{"id":31275,"date":"2025-04-07T14:47:26","date_gmt":"2025-04-07T06:47:26","guid":{"rendered":"https:\/\/flcube.com\/?p=31275"},"modified":"2025-04-07T14:47:27","modified_gmt":"2025-04-07T06:47:27","slug":"eli-lilly-secures-global-license-for-sangamos-stac-bbb-gene-therapy-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31275","title":{"rendered":"Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology"},"content":{"rendered":"\n

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY<\/a>) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO<\/a>), securing a worldwide exclusive license to Sangamo’s STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).<\/p>\n\n\n\n

Licensing Agreement Details<\/strong>
Under the terms of the agreement, Lilly gains the right to apply the STAC-BBB capsid to one initial target, with the option to add up to four additional targets upon payment of additional licensed target fees. This strategic move allows Lilly to advance its gene therapy portfolio, leveraging STAC-BBB’s unique properties to address challenging CNS diseases.<\/p>\n\n\n\n

Development and Commercialization<\/strong>
Sangamo will facilitate the technology transfer related to the STAC-BBB capsid, while Lilly assumes full responsibility for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of resulting gene therapy products.<\/p>\n\n\n\n

Financial Terms<\/strong>
Lilly will pay Sangamo an upfront fee of USD 18 million and has committed to up to USD 1.4 billion in additional licensed target fees and milestone payments. The agreement also includes tiered royalties based on net sales, subject to specified reductions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement…<\/p>\n","protected":false},"author":1,"featured_media":31276,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,66,2856,911,412],"class_list":["post-31275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eli-lilly","tag-gene-therapy","tag-nasdaq-sgmo","tag-nyse-lly","tag-sangamo-therapeutics"],"yoast_head":"\nEli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO), securing a worldwide exclusive license to Sangamo's STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31275\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO), securing a worldwide exclusive license to Sangamo's STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31275\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T06:47:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T06:47:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology\",\"datePublished\":\"2025-04-07T06:47:26+00:00\",\"dateModified\":\"2025-04-07T06:47:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275\"},\"wordCount\":221,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0703-png.webp\",\"keywords\":[\"Eli Lilly\",\"Gene therapy\",\"NASDAQ: SGMO\",\"NYSE: LLY\",\"Sangamo Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31275#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31275\",\"name\":\"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0703-png.webp\",\"datePublished\":\"2025-04-07T06:47:26+00:00\",\"dateModified\":\"2025-04-07T06:47:27+00:00\",\"description\":\"US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO), securing a worldwide exclusive license to Sangamo's STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31275\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0703-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0703-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31275#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology - Insight, China's Pharmaceutical Industry","description":"US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO), securing a worldwide exclusive license to Sangamo's STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31275","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology","og_description":"US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO), securing a worldwide exclusive license to Sangamo's STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).","og_url":"https:\/\/flcube.com\/?p=31275","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-07T06:47:26+00:00","article_modified_time":"2025-04-07T06:47:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31275#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31275"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology","datePublished":"2025-04-07T06:47:26+00:00","dateModified":"2025-04-07T06:47:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31275"},"wordCount":221,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31275#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp","keywords":["Eli Lilly","Gene therapy","NASDAQ: SGMO","NYSE: LLY","Sangamo Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31275#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31275","url":"https:\/\/flcube.com\/?p=31275","name":"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31275#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31275#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp","datePublished":"2025-04-07T06:47:26+00:00","dateModified":"2025-04-07T06:47:27+00:00","description":"US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement with Sangamo Therapeutics, Inc. (NASDAQ: SGMO), securing a worldwide exclusive license to Sangamo's STAC-BBB technology. This novel neurotropic adeno-associated virus (AAV) capsid demonstrates exceptional blood-brain barrier penetration and neuronal transduction capabilities in non-human primates, positioning it as a promising tool for delivering genomic medicines to the central nervous system (CNS).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31275#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31275"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31275#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp","width":1080,"height":608,"caption":"Eli Lilly Secures Global License for Sangamo's STAC-BBB Gene Therapy Technology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31275#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0703-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31275"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31275\/revisions"}],"predecessor-version":[{"id":31277,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31275\/revisions\/31277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31276"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}